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Objective
To determine if left ventricular hypertrophy (LVH) influ-
ences the prognostic utility of dobutamine cardiovascular
magnetic resonance (DCMR) stress test results.
Background
Although LVH is associated with adverse cardiovascular
outcomes and occurs in 10% to 25% of patients referred
for clinical DCMR stress testing, the influence of LVH on
the prognostic utility of DCMR wall motion stress test
results is unknown.
Methods
Three hundred sixty-two (362) participants, aged 64 ± 12
years (55% men) underwent DCMR for determination of
inducible ischemia, and then were followed for 6 ± 2
(range 0.5 to 11.5) years to assess the post-DCMR occur-
rence of MI or cardiac death assessed by researchers
blinded to the results of DCMR. Using previously estab-
lished criteria, LVH was defined as > 96 g/m2 in men and
> 77 g/m2 in women.
Results
LVH was present in 56 participants (16% of the men
and.15% of the women, referred for testing; p = 0.77).
Abnormal LV geometry was identified in 40% of the par-
ticipants with 24% concentric remodeling, 6% concentric
hypertrophy, and 10% eccentric hypertrophy. Seventy-
one (20%) participants experienced a MI or cardiac death.
The MI and cardiac death rate was more frequent in those
with versus those without LVH (32% vs. 17%, p = 0.01).
In a multivariable analysis that accounted for the presence
of pre-existing coronary artery disease, hypertension, dia-
betes, stress-induced ischemia, or reduced resting LVEF,
LVH was the independent predictor of MI and cardiac
death (HR 1.8, 95% CI 1.05-3.22, p = 0.032) Figure 1.
Conclusion
LVH forecasts future MI and cardiac death in patients with
chest pain referred for dobutamine cardiac stress testing.
LVH should be measured and reported in non-invasive
cardiac stress tests, particularly those without inducible
ischemia, in which otherwise one would assume a favora-
ble cardiac prognosis.
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